AbbVie Seeks Approval for Pediatric Use of Risankizumab in Psoriasis Treatments AbbVie has submitted additional approval applications for Risankizumab for treating pediatric patients with psoriasis and related conditions.

AbbVie Seeks Approval for Pediatric Use of Risankizumab in Psoriasis Treatments #Japan #pediatric_psoriasis #AbbVie #Minato-ku #Risankizumab

FDA Grants TREMFYA® Approval for Pediatric Psoriasis and Arthritis Treatment TREMFYA® is now FDA approved for the treatment of pediatric patients with plaque psoriasis and active psoriatic arthritis, offering new hope for children with these conditions.

FDA Grants TREMFYA® Approval for Pediatric Psoriasis and Arthritis Treatment #United_States #TREMFYA #pediatric_psoriasis #Horsham #Psoriatic_Arthritis

AbbVie Secures Rare Disease Designation for Risankizumab in Pediatric Generalized Pustular Psoriasis AbbVie has obtained rare disease designation for Risankizumab to treat pediatric patients with generalized pustular psoriasis in Japan, providing hope for better options.

AbbVie Secures Rare Disease Designation for Risankizumab in Pediatric Generalized Pustular Psoriasis #Japan #Tokyo #pediatric_psoriasis #AbbVie #Risankizumab

Johnson & Johnson Pursues FDA Approval for TREMFYA® to Treat Children Johnson & Johnson has filed applications to FDA for TREMFYA®, aiming to treat children with moderate-to-severe psoriasis and juvenile psoriatic arthritis.

Johnson & Johnson Pursues FDA Approval for TREMFYA® to Treat Children #United_States #Johnson_&_Johnson #Spring_House #TREMFYA #pediatric_psoriasis